129 related articles for article (PubMed ID: 38884296)
61. Imatinib Mesylate Induced Erythroderma.
Lunge S; Bhise R
J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
[TBL] [Abstract][Full Text] [Related]
62. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
63. Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection.
Luo ZB; Xu N; Huang XP; Ouyang GF
Turk J Haematol; 2017 Dec; 34(4):362-364. PubMed ID: 28753128
[No Abstract] [Full Text] [Related]
64. Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
Kaygusuz-Atagunduz I; Toptas T; Yumuk F; Firatli-Tuglular T; Bayik M
J Cancer Res Ther; 2014; 10(4):1107-8. PubMed ID: 25579564
[TBL] [Abstract][Full Text] [Related]
65. The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.
Nesr G; Claudiani S; Khorashad J; Apperley J; Milojkovic D
Leuk Lymphoma; 2019 Dec; 60(13):3333-3334. PubMed ID: 31232126
[No Abstract] [Full Text] [Related]
66. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
67. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
68. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
69. Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
Chandran RK; Geetha N; Sakthivel KM; Kumar RS; Krishna KMNJ; Sreedharan H
Blood Cells Mol Dis; 2019 Jul; 77():51-60. PubMed ID: 30959263
[TBL] [Abstract][Full Text] [Related]
70. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
71. Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls.
Bamgboje AO; Durosinmi MA; Mene-Afejuku TO; Fagbayimu MO; Fajobi O; Balogun MO
Vasc Health Risk Manag; 2022; 18():27-42. PubMed ID: 35210781
[TBL] [Abstract][Full Text] [Related]
72. An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
Paquin D; Sacco D; Shamshoian J
Math Biosci; 2015 Apr; 262():117-24. PubMed ID: 25659886
[TBL] [Abstract][Full Text] [Related]
73. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
74. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
[TBL] [Abstract][Full Text] [Related]
75. Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
Thapa M; Chaturvedi A
Postgrad Med J; 2020 May; 96(1135):296-297. PubMed ID: 31672761
[No Abstract] [Full Text] [Related]
76. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
77. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
78. Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study.
Merin D; Krishna A; Jayakumar S; Mahima A; Anila KN; Sidharthan N
J Oncol Pharm Pract; 2023 Apr; 29(3):547-556. PubMed ID: 35048760
[TBL] [Abstract][Full Text] [Related]
79. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
80. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH; Kim K; Song YK
Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
